| | | April 12, 2022 Welcome to the BRAND NEW Stock Dork Premarket Report, your go-to guide for the day's biggest trading news and hottest premarket stocks. Keep an eye out for our Premarket Reports moving forward and, as always, we invite you to reply to this email with your feedback, suggestions, or comments. It's Tuesday, April 12th. Let's get ready to trade! |
Stocks tumbled in Monday's trading session, with the Nasdaq selling off for 2.2%. The S&P 500 lost 1.7% on the day, and the Dow fell 1.2%. Small-caps in the Russell 2K ended the session with a 0.7% decline. Today, futures are pointing to a slightly higher open, with S&P 500 contracts showing a 0.1% gain. Aptiv PLC [APTV] - Last Close: $108.21 Aptive is surging on a round of new analyst upgrades. The vehicle component manufacturer is rallying today after Wells Fargo upgraded its rating on the stock to "equalweight" from its previous rating of "underweight:" Wells also raised its price target on APTV from $108 to $112.
Just yesterday, Exane BNP Paribas announced it was initiating coverage on APTV with an "outperform" recommendation and a $160 price target. Between the two bullish upgrades, shares of APTV are trending in the premarket. The stock is currently leading the S&P 500 with a 5.0% gain. Veru Inc [VERU] - Last Close: $4.35 Veru is on our list for the second day in a row as shares continue to surge. Upbeat Phase 3 trial results for Veru's treatment for Acute Respiratory Distress Syndrome relating to COVID-19 lifted the stock to a 182.3% gain by the time yesterday's session closed, and we sounded the alert when it was up just 25% in the premarket. If you jumped in on this trade, you could've seen strong returns on your initial position. However, the surge didn't subside in the after-hours trading session, and shares are continuing to rally in today's premarket. Today, shares are up another 14.0% in today's premarket, on top of yesterday's 182% surge. Biodesix [BDSX] - Last Close: $1.59 Biodesix is up big on news of a successful private placement. The data-driven diagnostics company announced this morning that it had successfully entered into private placement agreements with a consortium of investors, including three board members and existing shareholders, to issue and sell more than 6.5 million shares of its stock. The investors paid $1.79 apiece to acquire the newly-minted shares, equivalent to the closing price on April 7th. Altogether, the price tag for the new shares came out to about $11.7 million, according to a Biodesix's regulatory filing. BDSX is trading actively with a 50.9% gain. Biocardia [BCDA] - Last Close: $2.15 News of a new drug approval is lifting shares of Biocardia in today's premarket. This morning, the clinical-stage regenerative medicine company announced the US Food & Drug Administration approved the firm's Investigational New Drug (IND) application for BCDA-04. The FDA decision clears the way for Biocardia to begin first-in-human Phase I/II trials in adult patients recovering from Acute Respiratory Distress Syndrome resulting from COVID-19. Biocardia says it expects to initiate the trial sometime in the third quarter. BCDA is up 54.9% on active trading volume following the premarket announcement. |
| Gainers Polaryte Inc [PTE] >> +92.67% RLC Technology [RLX] >> +12.8% Cyclacel [CYCC] >> +25.0% Decliners Hoth Therapeutics [HOTH] >> (21.9%) Myovant Sciences [MYOV] >> (21.4%) Alset Ehome Intl [AEI] >> (18.7%) CarMax [KMX] ... AM Albertsons Companies [ACI] ... AM Evotec [EVO] ... AM OrganiGram [OGI] ... AM |
| NFIB Small-Business Index [Mar] ... 6a Consumer Price Index [Mar] ... 8:30a Federal Budget Deficit [Mar] ... 2p |
| Thanks for reading! Don't forget, I'm always eager to hear from you. Reply to this email with your questions, comments, or general feedback, and Ill get back to you as soon as I can. Wishing you big returns on your investments this week, as always! - Michael "The Dork" Taylor P.S. Want My Alerts Delivered To Your Cell Phone? Sign up for mobile alerts and get the latest updates delivered to your cell. Disclaimer Ă© 2022 TheStockDork.com. All rights reserved. This message was sent by TheStockDork.com and may contain commercial elements such as advertising. Read full terms here. |
|
|
|
| | |
|
